Kymera Launches Phase 2b Trial for New Atopic Dermatitis Drug
Kymera has begun dosing in BROADEN2, a 16-week, randomized, double-blind, placebo-controlled Phase 2b study of KT-621 in moderate to...
New ENIGMAC Data Reveals Macrophage Role in Fibrotic Disease
Macomics has validated its ENIGMAC macrophage discovery platform in antifibrotic biology, completing pooled and arrayed CRISPR-based gene modulation screens...
Junshi Announces Successful Phase 3 NSCLC Study Results
Junshi Biosciences reported that its Phase 3 JS001sc-002-III-NSCLC study met primary endpoints, showing non-inferior drug exposure for subcutaneous toripalimab...
AI-enabled eConsent: Balancing Personalization with Human Oversight
In this interview, Vinita Navadgi, Sr. Director, Digital Patient Suite, IQVIA, shares a practical, thought-leading view on AI-driven electronic...
Gelteq’s Promising Gel Tech: A Bioavailability Victory
Gelteq reported a 38–45% increase in AUC and a markedly higher Cmax versus a marketed reference antihistamine in a...
Important New Elzonris Data Presented at Hematology Meeting
Menarini and Stemline will bring five ELZONRIS (tagraxofusp) data sets to ASH 2025, headlined by an oral Phase 2...
Cidara’s Phase 3 Flu Prevention Trial Hits Target Enrollment
Cidara completed enrollment of 6,000 participants in its Phase 3 ANCHOR trial of CD388, a single 450 mg subcutaneous...
Vertero Starts Phase 1 Study for Parkinson’s Therapy VT-5006
Vertero Therapeutics has opened a Phase 1 program for VT-5006, an oral, gut-selective small molecule intended for Parkinson’s disease...
New CREST-2 Study Confirms Carotid Stenting Benefits
In CREST-2, carotid artery stenting added to intensive medical therapy significantly reduced the composite of perioperative stroke or death...
Avadel Board Declares Lundbeck Proposal a Superior Offer
Up to $23.00 per share for Avadel, valuing the company at roughly $2.4 billion: $21.00 in cash at closing...